A recent increase in stimulant treatment of adolescents with attention deficit hyperactivity disorder (ADHD) has been documented. Challenges in treating adolescent ADHD with methylphenidate or dextroamphetamine include compliance with frequent dosing, abuse potential and wear-off or rebound effects. Co-morbid anxiety, occurring in at least 30 percent of ADHD youths, is associated with lower rate of response to stimulants. The effective alternatives, tricyclic antidepressants or pemoline, are each associated with rare but serious toxicity. Bupropion has recently proven effective in controlled trials. Other noradrenergic or dopamine-enhancing agents such as venlafaxine and nicotine show some benefit in open trials. The need for more options in pharmacotherapy of ADHD is evidenced by rapid adoption in clinical practice of alternative and adjunctive medication despite lack of controlled research on efficacy and safety.
The indications for long-term stimulant treatment of ADHD present some controversy, and highlight a need for more research on safety and efficacy through the lifespan. Thresholds for diagnosis are much lower with DSM than with ICD, and thresholds for treatment are contentious, given the performance-enhancing effects of stimulants in normal students. The endpoint for treatment is unclear, as stimulants are also effective in adult ADHD. Based on short- and intermediate-term studies to date, stimulant medication is clearly more efficacious than cognitive and behavioral strategies for the symptoms of ADHD. Longer term research is needed to determine whether sustained stimulant therapy will reduce the adverse emotional, behavioral and academic consequences of inattention and impulsivity in adolescents and adults.
Abikoff H., Gittelman R. (1985) Hyperactive children treated with stimulants: is cognitive training a useful adjunct? Archs Gen Psychiat42: 953-961
2.
Adler L.A., Resnick S., Kunz M., Devinsky O. (1995) Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmac Bull31: 785-788
3.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
4.
Arnold L.E., Abikoff H.B., Cantwell D.P., Connors K., Elliott G., Greenhill L.L., Hechtman L., Hinshaw S.P., Hoza B., Jensen P.S., Kraemer H.C., March J.S., Newcorn J.H., Pelham W.E., Richters J.E., Schiller E., Severe J.B., Swanson J.M., Vereen D., Wells KC (1997) National Institute of Mental Health collaborative multimodal treatment study of children with ADHD (the MTA). Design challenges and choices. Archs Gen Psychiat54: 865-870
5.
Barkley R.A., DuPaul G.J., McMurray M.B. (1990a) A comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol58: 775-789
6.
Barkley RA, Fischer M., Edelbrook CS, Smallish L. (1990b) The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8 year prospective follow-up study. J Am Acad Child Adolesc Psychiat29: 546-557
7.
Barkley R.A., DuPaul G.J., McMurray M.B. (1991) Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics87: 519-531
8.
Barrickman L., Noyes R., Kuperman S. (1991) Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiat30: 762-767
9.
Barrickman LL, Perry PJ, Allen AJ, Kuperman S., Arndt SV, Herrmann KJ, Schumacher E. (1995) Bupropion vs methylphendiate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiat34: 649-657
10.
Baumgaertel A., Wolraich M.L.Dietrich M. (1995) Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiat34: 629-638
11.
Berkovitch M., Pope E., Phillips J., Koren G. (1995) Pemoline-associate fulminant liver failure: testing the evidence for causation. Clin Pharmac Ther57: 696-698
12.
Biederman J., Baldesarini R., Wright V., Knee D., Harmatz J. (1989) A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder. I. EfficacyJ Am Acad Child Adolesc Psychiat28: 777-784
13.
Biederman J., Newcorn J., Sprich S. (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatr148: 564-577
14.
Biederman J., Thisted R.A., Greenhill L.L., Ryan N.D. (1995a) Estimation of the association between desipramine and the risk for sudden death in 5 to 14 year old children. J Clin Psychiat56: 87-93
15.
Biederman J., Wilens T., Mick E., Milberger S.Spencer TJ, Faraone S.V. (1995b) Psychoactive substance abuse disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiat152:1652-1658
16.
Biederman J., Faraone S., Milberger S., Guite J., Mick E., Chen L. et al. (1996a) A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Archs Gen Psychiat53: 437-446
17.
Biederman J., Faraone S., Mick et al. (1996b) Attention-defict hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Pscychiatry35: 997-1008
18.
Biederman J., Wilens T., Mick E., Faraone S.V., Weber W., Curtis S., Thornell A., Pfister K., Jetton JG, Soriano (1997) Is ADHD a risk factor for psychoactive substance abuse disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiat36: 21-29
19.
Buitelaar J.K., Van der Gaag R.J., Swaab-Barneveld H.Kuiper M. (1996) Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side effects. J Child Psychol Psychiat Allied Disc37: 587-967
20.
Campbell S.B., Douglas V.I., Morgenstern G. (1971) Cognitive styles in hyperactive children and the effect of methylphendiate. J Child Psychol Psychiat12: 55-67
21.
Campbell M., Adams P.B., Small A.M., Kafantaris V., Silva R.R., Shell J., Perry R., Overall J.E. (1995) Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo controlled study. J Am Acad Child Adolesc Psychiat34: 445-453
22.
Cantwell D.P. (1996) Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiat35: 978-987
23.
Cantwell D.P., Swanson J., Connor D. (1997) Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiat36: 539-544
24.
Casat C.D., Pleasants D.Z., Van Wyk Fleet J. (1987) A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmac Bull23: 198-20
25.
Castellanos F.X. (1997) Neuroimaging of attention deficit hyperactivity disorder. Child Adolesc Psychiat Clin N Am6: 383-411
26.
Castellanos F.X., Giedd J.N., Elia J., Marsh W.L., Ritchie G.F., Hamburger S.D., Rapoport J.L. (1997) Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiat36: 589-596
27.
ClayT H., Gualtieri C.T., Evans R.W., Guillion C.M. (1988) Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmac Bull23: 120-122
28.
Conners C.K. (1969) A teacher rating scale for use in drug studies with children. Am J Psychiat126: 884-888
Conners CK, Taylor E. (1980) Pemoline, methylphenidate and placebo in children with minimal brain dysfunction. Archs Gen Psychiat37: 922-932
31.
Conners C.K., Taylor E., Meo G., Kurtz M.A., Fournier M. (1972) Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction. Psychopharmacologia26: 321-336
32.
Conners C.K., Casat C.D., Gualtieri T., Weller E., Reader M., Reiss A., Weller RA, Khayrallah M., Ascher J. (1996a) Bupropion hypdrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiat35: 1314-1321
33.
Conners C.K., Levin ED, Sparrow E., Hinton S.C., Erhardt D., Meck W.H., Rose J.E., March J. (1996b) Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmac Bull32: 67-73
34.
Cromer BA, Tarnowski (1989) Noncompliance in adolescents: a review. Dev Behav Pediat10: 207-215
35.
Cueva J.E., Overall J.E., Small AM, Armenteros J.L., Perry R., Campbell M. (1996) Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiat35: 480-490
36.
Denckla M.B. (1996) Biological correlates of learning and attention: what is relevant to learning disability and attention-deficit hyperactivity disorder? J Dev Behav Pediat17: 114-119
37.
Diller L.H. (1996) The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Center Rep26: 12-18
38.
Douglas V.I., Barr R.G., Desilets J., Sherman E. (1995) Do high doses of stimulants impair flexible thinking in attention-defict hyperactivity disorder? J Am Acad Child Adolesc Psychiat34: 877-885
39.
Elia J., Borcherding B., Rapoport J., Keysor C. (1991) Methylphenidate and detroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiat Res36:141-155
40.
Feigin A., Kurlan R., McDermott M.P., Beach J. et al. (1996) A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology46: 965-968
41.
Friedmann N., Thomas J., Carr R., Elders J., Ringdahl I., Roche A. (1981) Effect on growth in pemoline-treated children with attention deficit disorder. Am J Dis Child135: 329-332
42.
Gadow K.D., Nolan E.E., Sverd J., Sprafkin J., Paolicelli L. (1990) Methylphenidate in aggressive-hyperactive boys. I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiat29: 710-718
43.
Gadow K.D., Nolan E., Sprafkin J., Sverd J. (1995a) School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediat16: 167-176
44.
Gadow K.D., Sverd J., Sprafkin J., Nolan E., Ezor S.N. (1995b) Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Archs Gen Psychiatry52: 444-455
45.
Gammon G.D., Brown T.E. (1993) Fluoxetine augmentation of methylphenidate for attention deficit and comorbid disorders. J Child Adolesc Psychopharmac3: 1-10
46.
Gillberg C., Melander H., von Knorring A-L., Janols L-O.,Thernlund G., Hagglof B., Eidevall-Wallin L., Gustafsson P., Kopp S. ( 1997) Longterm stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. Archs Gen Psychiat54: 857-864
47.
Gittelman R., Abikoff H., Pollack E., Klein D.F., Katz S., Mattes J. (1980) Behavior therapy and methylphenidate for hyperactive children. In Whalen C K, Henker B, (eds), Hyperactive children: the social ecology of identification and treatment. Academic Press, New York, pp. 221-243
48.
Greenhill L.L., Abikoff H.B., Arnold L.E., Cantwell D.P., Conners C.K., Elliott G., Hechtman L., Hinshaw S.P., Hoza B., Jensen P.S., March J.S., Newcorn J., Pelham W.E., Severe J.B., Swanson J.M., Vitiello B., Wells K. (1996) Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiat35: 1304-1313
49.
Gwirtsman H.E., Szuba M.P., Toren L., Feist M. (1994) The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmac Bull30: 157
50.
Hedges D., Reimherr F.W., Rogers A., Strong R., Wender PH (1995) An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmac Bull31: 779-783
51.
Hinshaw S.P., Heller T., McHale J.P. (1992) Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphendiate . J Consult Clin Psychol60: 274-281
52.
Horn W.R., Ialongo N.S., Pascoe J.M., Greenberg G., Packard T., Lopez M., Wagner A., Puttler L. (1991) Additive effects of psychostimulants, parent training, and self-control therapy with ADHD children. J Am Acad Child Adolesc Psychiat30: 233-240
53.
Hunt R.D. (1987) Treatment effects of oral and transdermal clonidine in relation to methylphendiate—an open pilot study in ADHD. Psychopharmac Bull23: 111-114
54.
Hunt R.D., Minderaa R.B., Cohen D.J. (1985) Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adolesc Psychiat24: 617-629
55.
Hunt R.D., Arnsten A F T, Asbell M.D. (1995) An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatr34: 50-54
56.
Ialongo N.S., Horn W.F., Pascoe J.M., Greenberg G., Packard et al. (1993) The effects of a multimodal intervention with attention deficit hyperactivity disorder children: a 9 month follow-up. J Am Acad Child Adolesc Psychiat32:182-189
57.
Jacobvitz D., Sroufe L.A., Stewart M., Leffert N. (1990) Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiat29: 677-688
58.
Jaffe S.L. (1991) Intranasal abuse of prescribed methylphendiate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiat30: 774-775
59.
Johnson A., Guiffre R.M., O'Malley K. (1996) ECG changes in pediatric patients on tricyclic antidepressants, desipramine and imipramine. Can J Psychiat41: 102-106
60.
Johnston JA, Lineberry CG, Ascher JA et al. (1991) A 102-center prospective study of seizures in assocation with bupropion. J Clin Psychiat52: 450-456
61.
Jureidini J. (1996) Some reasons for concern about attention deficit hyperactivity disorder. J Pediatr Child Hlth32: 201-203
62.
Kent J.D., Blader J.C., Koplewicz H.S., Abikoff H., Foley C.A. (1995) Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics96: 320-325
63.
Kutcher, S. (1997). Child and adolescent psychopharmacology. W B Saunders, Philadelphia, PA, pp. 273-294
64.
Langer D.H., Sweeney K.P., Bartenbach D.E., Davis P.M., Menander K.B. (1986) Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend17: 213-227
65.
Leung P.W., Luk S.L., Ho T.P., Taylor E., Mak F.L., Bacon-Shone J. (1996) The diagnosis and prevalence of hyperactivity in Chinese school-boys. Brit J Psychiat168: 4860-496
66.
Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., Rose JE, March J. (1996) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology123: 55-63
67.
Levy F., Hobbes G. (1996) Does haloperidol block methylphenidate? Motivation or attention? Psychopharmacology126: 70-74
68.
Levy F., Hay DA, McStephen M., Wood C., Waldman I. (1997) Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiat36: 737-744
69.
Mattes J. (1980) A pilot trial of amantadine in hyperactive children . Psychopharmac Bull16: 67-69
70.
Milberger S., Biederman J., Faraone S.V., Chen L., Jones J. (1997) ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiat36: 37-44
71.
Murphy D., Pelham W., Lang A. ( 1992) Aggression in boys with ADHD. Methylphenidate effects on naturalistically observed aggression, response to provocation and social information processing. J Abnorm Child Psychol20: 451-466
72.
Nada-Raja S., LangleyJ., McGee R.,Williams S.M., Begg D.J., ReederA I. (1997) Inattentive and hyperactive behaviors and driving offences in adolescence. J Am Acad Child Adolesc Psychiat36: 515-522
73.
Nolan E.E., Gadow K.D. (1997) Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphendiate. J Am Acad Child Adolesc Psychiat36: 597-604
74.
Pataki C., Carlson G., Kelly K., Rapport M., Biancaniello T. (1993) Side effects of methylphenidate and desipramine alone and in combination in children. Am J Psychiat32: 1065-1072
75.
Parran TV, Jasinski DR (1991) Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Int Med151: 781-783
76.
Pelham W.E., Bender Me, Caddell J, Booth S., Moorer SA (1985) Methylphenidate and children with attention deficit disorder: dose effects on classroom academic and social behavior. Arch Gen Psychiat42: 948-952
77.
Pelham W.E., Sturges J., Hoza J., Schmidt C., Bijlsma JJ, Milich R., Moorer S. (1987) Sustained release and standard methylphendiate effects on cognition and social behavior in children with attention deficit disorder. Pediatrics80: 491-501
78.
Pelham WE, Walker J.L., Sturges, J.Hoza J. ( 1989) Comparative effects of methylphenidate on ADD girls and boys. J Am Acad Child Adolesc Psychiat28: 773-776
79.
Pelham W., Greenslade K., Vodde-Hamilton M. et al. (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained release methylphenidate, sustained release dextroamphetamine and pemoline. Pediatrics86: 226-237
80.
Pelham WE, Vodde-Hamilton M., Murphy DA, Greenstein J., Vallano G. (1991) The effects of methylphenidate on ADHD adolescents in recreational, peer group and classroom settings. J Clin Child Psychol20:293-300
81.
Pelham WE, Swanson J.M., Furman M.B., Schwindt H. (1995) Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiat34: 1504-1513
82.
Pizzuti D. (1996) Letter to physicians. Abbott Laboratories Pharmaceutical Products Divison, Medical Services Department , Abbott Park, Chicago, IL, USA
83.
Pliszka S.R. (1989) Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiat28: 882-887
84.
Pliszka S.R., McCracken J.T., Maas J.W. (1996) Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiat35: 264-272
85.
Pratt D.S., Dubois R.S. (1990) Hepatotoxicity due to pemoline: a report of two cases. J Pediatr Gastroenterol Nutr10: 239-241
86.
Prendergast N., Taylor E., Rapoport J.L., Bartko J., Donnelly M., Zametkin A., Ahearn M.B., Dunn G.Wieselberg H.M. (1988) The diagnosis of childhood hyperactivity: a US-UK cross-national study of DSMIII and ICD-9. J Child Psychol Psychiat35: 599-605
87.
Priest RG, Gimbrett R., Roberts N., Steinart (1995) Reversible and selective inhibitors of monoamine oxidase in mental and other disorders. Acta Psychiat Scand386 (Suppl.): 40-43
88.
Prince J.B., Wilens T.E., Biederman J., Spencer TJ, Wozniak J.R. (1996) Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adoles Psychiat35: 599-605
89.
Rapoport J.L., Quinn P., Bradbard G., Riddle D., Brooks E. (1974) Imipramine and methylphenidate treatment of hyperactive boys: a double-blind comparison. Archs Gen Psychiat30: 789-793
90.
Rapoport J.L., Buchsbaun M.S., Zahn T.P., Weingartner H., Ludlow C., Mikkelsen E.J. (1978) Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science199: 560-563
91.
Rapport M., Denney C., DuPaul G.J., Gardner M.J. (1994) Attention deficit disorder and methylphemdate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiat33: 882-893
92.
Riddle M.A., King R.A., Hardin M.T. et al. (1991) Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmac1:193-198
93.
Riddle M.A., Geller B., Ryan N.D. (1994) The safety of desipramine. J Am Acad Child Adolesc Psychiat33: 589-590
94.
Riggs P.D. (1998) Clinical approach to treatment of ADHD in adolescents with substance abuse disorders and conduct disorder. J Am Acad Child Adolesc Psychiat37: 331-332
95.
Riggs P.D., Thompson L.L., Mikulich S.K., Whitmore E.A., Crowley TJ (1996) An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiat35: 1018-1024
96.
Robbins T.W., Everitt B.J. (1996) Neurobehavioral mechanisms of reward and motivation . Curr Opin Neurobiol6: 228-236
97.
Safer D.J., Allen R.P. (1975) Stimulant drug treatment of hyperactive adolescents . Dis Nerv Sys36: 454-457
98.
Safer D.J., Krager J.M. (1994) The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics94: 462-464
99.
Safer DJ, Zito JM, Fine EM ( 1996) Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics98: 1084-1088
100.
Satterfield J.H., Satterfield B.T., Schell A.M. (1987) Therapeutic interventions to prevent delinquency in hyperactive boys. J Am Acad Child Adolesc Psychiat26: 56-64
101.
Schachar R., Hoppe C., Schell A. (1987) Changes in family function and relationships in children who respond to methylphendiate. J Am Acad Child Adoles Psychiat26: 728-732
102.
Schachar R.J., Tannock R., Cunningham C., Corkum P.V. (1997) Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiat36: 754-763
103.
Schweitzer J.B., Sulzer-Azaroff B. (1994) Self-control in boys with attention deficit hyperactivity disorder: effects of added stimulation and time. J Child Psychol Psychiat36: 671-686
104.
Sherman D.K., McGue M.K., Iacono W.G. (1997) Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Am J Psychiat154: 532-535
105.
Simeon JG, Ferguson H.B., Van-Wyck-Fleet J. (1986) Bupropion effects in attention deficit and conduct disorders. Can J Psychiat31: 581-585
106.
Silva RR, Munoz DM, Alpert M. (1996) Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis. J Am Acad Child Adoles Psychiat35: 352-358
107.
Smith, B.H., Pelham W.E., Gnagy E., Yudell, R.S. (1998) Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiat37: 314-321
108.
Sonuga-Barke E F S, Taylor E., Sembi S., Smith J. (1992) Hyperactivity and delay aversion: 1. the effect of delay on choice. J Child Psychol Psychiat32: 909-938
109.
Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon S., Lapey K. (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Archs Gen Psychiat52: 434-443
110.
Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. (1996a) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiat35: 409-432
111.
Spencer T.J., Biederman J., Harding M., O'Donnell D.Faraone S.V.Wilens T.E. (1996b) Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiat35: 1460-1469
112.
Sprague R., Sleator E. (1977) Methylphemdate in hyperkinetic children: differences in dose effects on learning and social behavior. Science198:1274-1276
113.
Stein M.A., Blondis R.A., Schnitzler E.R., O'Brien T., Fishkin J., Blackwell B. (1996) Methylphendiate dosing: twice daily versus three times dailyPediatrics98: 748-756
114.
Stoll A.L., Pillay S.S., Diamond L., Workum S.B., Cole JO ( 1996) Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiat56: 72-76
115.
SwansonJ.M., Flockart D., Udrea D., Cantwell D.P., Connor D.,Williams L. (1995) Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmac5: 301-304
116.
Tannock R., Schachar R., Logan G. (1995a) Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol23: 235-266
117.
Tannock R., Ichowica A., Schachar R. (1995b) Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiat34: 886-896
118.
Teicher M.H., Ito Y., Glod CA, Barber N.I. (1996) Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psyuchiat35: 334-342
119.
Trott G.E.Friese H.J., Menzel M., Nissen G. (1991) Use of moclobemide in children with attention deficit hyperactivity disorder. Jugendpsychiat19: 248-253 (in German)
120.
Varley C. (1983) Effects of methylphenidate in adolescents with attention defciti disorder. J Am Acad Child Adolesc Psychiat22: 351-354
121.
Volkow N.D., Wang G.J., Fowler J.S., Logan G., Angrist B., Hitzemann R. et al. (1997) Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors . Am J Psychiat154: 50-55
122.
Warburton D.M., Arnall C. (1994) Improvements in performance without nicotine withdrawal . Psychopharmac115: 539-542
123.
Weiss G., Hechtman LT (1993) Hyperactive children grown up, 2nd edn. Guildford Press, New York
124.
Werry J.S. (1994) The safety of desipramine. J Am Acad Child Adolesc Psychiat33: 588-589
125.
Whalen C., Hencker B., Swanson J., Granger D. (1990) Social judgement processes in hyperactive boys: effects of methylphendiate and comparisons with normal peers. J Abnorm Child Psychol18: 297-316
126.
Wilens T., Biederman J., Spencer T., Prince J. (1995) Pharmacotherapy of adult attention deficit hyperactivity disorder: a review. J Clin Psychopharmac15: 270-279
127.
Wilens T.E., Biederman J., Spencer TJ (1997) Adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiat36: 45-48
128.
Wolraich M.L., Hannah J.N., Pinnock T.Y., Baumgartel A., Brown J. (1996) Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiat35: 319-324
129.
World Health Organization (1992) The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
130.
Zametkin, A.J., Rapoport J.L., Murphy D. (1986) Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Archs Gen Psychiat42: 962-966
